Oncologic outcomes after robot assisted radical cystectomy in patients with clinically positive lymph nodes (cN1): a tertiary referral center experience

Le résumé fourni par la source

BACKGROUND: The aim of the article is to assess perioperative and oncological features of patients with clinically positive lymph nodes treated with RARC wit intracorporeal urinary diversion in a large contemporary cohort. METHODS: Consecutive patients treated from January 2016 to January 2025 with RARC, lymph node dissection (LND) and intracorporeal reconfiguration for cT1-3 N0-N1 M0 BCa were included. Follow-up schedule included blood analysis and CT scan performed three months after surgery, then every 6 months from the first to the third postoperative year, followed by annual imaging. RESULTS: Overall, 324 patients treated with RARC + LND were included. Of these, the 19% was female. The median age was 69 (61-75) years while the median CCI was 3 (2-4). In terms of intraoperative features, no significant differences were recorded with a median operative time was 366 (317-396) vs. 377 (312-442) minutes while an extended LND template was performed in the 39 vs. 49% of cases in the cN0 and cN1 groups, respectively (P=0.015). Overall postoperative complications occurred in the 28% of patients and the rate of major complications was not different between the two groups (9.1 vs. 13%, P=0.9). After a median follow-up of 38 (24-45) months, disease free survival was 69 vs. 34% with a median time to recurrence of 12 vs. 9 months in the cN0 and cN1 groups (P=0.05 and P=0.04, respectively). In terms of survival analyses, the cN1 groups was associated with significantly lower rates of CSS (79 vs. 40.2%, P=0.001), and OS (65 vs. 33%, P=0.001, respectively). CONCLUSIONS: In a cohort of cN1 patients, RARC shows worthy oncological outcomes with disease recurrence and cancer-specific mortality rates consistent to open surgical series and no evidence of atypical recurrences.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.